Wellington Management Group LLP Makes New Investment in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Wellington Management Group LLP acquired a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 87,958 shares of the company's stock, valued at approximately $6,342,000. Wellington Management Group LLP owned about 0.18% of Prestige Consumer Healthcare as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Blue Trust Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 106.9% during the second quarter. Blue Trust Inc. now owns 867 shares of the company's stock worth $63,000 after purchasing an additional 448 shares during the period. Raymond James & Associates lifted its holdings in Prestige Consumer Healthcare by 10.1% during the 2nd quarter. Raymond James & Associates now owns 117,802 shares of the company's stock worth $8,111,000 after buying an additional 10,823 shares during the period. Louisiana State Employees Retirement System increased its stake in shares of Prestige Consumer Healthcare by 2.0% in the second quarter. Louisiana State Employees Retirement System now owns 25,100 shares of the company's stock valued at $1,728,000 after buying an additional 500 shares during the period. Bailard Inc. bought a new position in shares of Prestige Consumer Healthcare during the second quarter worth about $213,000. Finally, Allspring Global Investments Holdings LLC raised its position in shares of Prestige Consumer Healthcare by 26.0% during the second quarter. Allspring Global Investments Holdings LLC now owns 1,320,125 shares of the company's stock worth $90,891,000 after acquiring an additional 272,773 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Stock Down 2.0 %

Shares of Prestige Consumer Healthcare stock traded down $1.60 during trading on Tuesday, reaching $80.39. 395,306 shares of the company traded hands, compared to its average volume of 252,265. The firm has a market capitalization of $3.97 billion, a PE ratio of 19.95, a P/E/G ratio of 2.32 and a beta of 0.49. Prestige Consumer Healthcare Inc. has a 1-year low of $57.95 and a 1-year high of $86.36. The company has a 50 day moving average price of $78.41 and a 200-day moving average price of $72.74. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company had revenue of $283.79 million for the quarter, compared to analysts' expectations of $282.09 million. During the same quarter in the prior year, the firm earned $1.07 EPS. The business's revenue was down .9% on a year-over-year basis. As a group, equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. StockNews.com downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Tuesday, December 10th. Sidoti downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 target price for the company. in a research note on Monday, December 9th. DA Davidson restated a "buy" rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Finally, Jefferies Financial Group reiterated a "hold" rating and set a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $85.25.

Insider Transactions at Prestige Consumer Healthcare

In related news, EVP Adel Mekhail sold 9,063 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the sale, the executive vice president now directly owns 18,365 shares of the company's stock, valued at approximately $1,505,930. This trade represents a 33.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider William P'pool sold 8,987 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total value of $735,585.95. Following the sale, the insider now owns 20,058 shares in the company, valued at $1,641,747.30. This trade represents a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,810 shares of company stock valued at $3,187,300 over the last ninety days. 1.60% of the stock is currently owned by insiders.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.